The pathophysiology of target organ damage in hypertension

Minerva Cardioangiologica

Volumn 54, Issue 4, 2006, Pages 417-429

  Karpha, M ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Hypertension, diagnosis; Hypertension, physiopathology; Target organ damage

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; THROMBOPLASTIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; INFLAMMATION; PATHOGENESIS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TARGET ORGAN; THROMBOCYTE ACTIVATION; THROMBOSIS;

HUMANS; HYPERTENSION; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSIS;

EID: 33750607143     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Kearney P, Whelton M, Reynolds K, Muntner P, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
4. Levenson JW, Skerrett PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol 2002;5:188-99.
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Eng J Med 1990;322:1561-6.
6. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996;78:197-202.
7. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;24:983-91.
8. Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002;13:505-12.
9. Simon G, Altman S. Subpressor angiotensin II is a bifunctional growth factor of vascular muscle in rats. J Hypertens 1992;10:1165-71.
10. Simon G. Synergistic effect of angiotensin II and a high sodium diet on the vascular glycosaminoglycan synthesis of rats. Am J Hypertens 1997;10:1216-22.
11. Tedesco MA, Ratti G, Aquino D, Limongelli G, di Salvo G, Mennella S et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998;12:505-10.
12. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic hypertension. Am J Cardiol 1993;71:12A-16A.
13. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post acute myocardial infarction pathology. Am J Cardiol 2006;97:4F-12F.
14. Karter Y, Aydin S, Curgunlu A, Uzun H, Erturk N, Vehid S et al. Endothelium and angiogenesis in white coat hypertension. J Hum Hypertens 2004;18:809-14.
15. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990;81:1762-7.
16. Felmeden D, Nadar SK, Lip GY. Aspirin and endothelial function in hypertension. J Hum Hypertens 2005;19:663-5.
17. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995;91:1981-7.
18. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Investig 1990;86:228-34.
19. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A et al. Passive smoking and impaired endothelium dependent arterial dilatation in healthy young adults. N Engl J Med 1996;334:150-4.
20. Taddei S, Virdis A, Mattei P, Arzilli F, Salvetti A. Endothelium dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992;20 Suppl 12:S193-S195.
21. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A 1991;88:10045-8.
22. Tschudi MR, Luscher TF. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation 1995;91:2415-22.
23. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium derived relaxing factor. Nature 1986;320:454-60.
24. Rubyani GM, Vanhoutte PM. Superoxide anions and hyperoxia inactive endothelium derived relaxing factor. Am J Physiol 1986;250:H822-H827.
25. Wu X, Makynen H, Kahonen M, Arvola P, Porsti I. Mesenteric arterial function in vitro in three models of experimental hypertension. J Hypertens 1996;14:365-72.
26. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639-46.
27. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Investig 1989;83:1774-7.
28. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 1995;96:141-9.
29. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991;88:4651-5.
30. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
31. Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Blood Coagul Fibrinolysis 2003;14:425-31.
32. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003;16:11-20.
33. Nadar SK, Blann A, Beevers DG, Lip GYH. Abnormal angiopoetins 1&2, angiopoetin receptor tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Intern Med 2005;258:336-43.
34. Nadar SK, Tayebjee MH, Messerli F, Lip GYH. Target organ damage in hypertension: Pathophysiology and implications for drug therapy. Curr Pharm Des 2006;12:1581-92.
35. Sullivan JM, Prewitt RL, Josephs JA. Attenuation of the microcirculation in young patients with high output borderline hypertension. Hypertension 1983;5:844-51.
36. Struijker HA. The microcirculation in hypertension. J Hypertens 1992;10 Suppl 7:147.
37. Felmeden DC, Blann AD, Lip GYH. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003;24:586-603.
38. Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Cardiol 2003;92:400-5.
39. Loomans CJ, Dao HH, Zonneveld AJ, Rabelink TJ. Is endothelial progenitor cell dysfunction involved in altered atherogenic processes in patients with hypertension. Curr Hypertens Res 2004;6:51-4.
40. Tao J, Wang Y, Yang Z, Tu C, Xu MG, Wang JM. Circulating endothelial progenitor cell deficiency contributes to impaired arterial elasticity in persons of advancing age. J Hum Hypertens 2006;20:490-5.
41. Lip GYH. Hypertension, platelets and the endothelium. The thrombotic paradox of hypertension revisited. Hypertension 2003;41:199-200.
42. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-97.
43. Jaffe EA. Cell biology of endothelial cells. Hum Pathol 1987;18:234-9.
44. Nemerson Y, Giesen PL. Some thoughts about localisation and expression of tissue factor. Blood Coagul Fibrinolysis 1998;9 Suppl 1:S45-S47.
45. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993;91:2253-9.
46. Berrettini M, Schleef RR, Espana F, Loskutoff DJ, Griffin JH. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. J Biol Chem 1989;264:11738-43.
47. Loscalzo J, Schafer AI. Thrombosis and haemorrhage. Boston, Mass.: Blackwell Scientific Publications; 1994.
48. Vaughan DE. Angiotensin and vascular fibrinolysis balance. Am J Hypertens 2002;15:S3-S8.
49. Tomiyama H, Kimura Y, Mitsuhashi H, Kinouchi T, Yoshida H, Kushiro T et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 1998;31:321-7.
50. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or Atenolol. Am J Hypertens 2000;13:783-8.
51. Aigbe A, Famodu AA. Haemorheological and fibrinolytic activity in hypertensive Nigerians. Clin Hemorheol Microcirc 1999;21:415-20.
52. Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997;80:1566-71.
53. Seiss W. Molecular mechanisms of platelet activation. Physiol Rev 1989;69:58-178.
54. Nurden AT, Bihour C, Macchi L, Lacaze D, Durrieu C, Besse P et al. Platelet activation in thrombotic disorders. Nouv Rev Fr Hematol 1993;35:67-71.
55. Kawai Y, Handa M, Nagai H, Kamata T, Anbo H, Kawano K et al. Role of membrane glycoproteins in the interaction of blood platelets with the vessel wall: the study on platelet adhesion to in vitro cultured subendothelial matrix. Nippon Ketsueki Gakkai Zasshi 1989;52:1312-21.
56. Blann AD, Nadar S, Lip GY. Pharmacological modulation of platelet function in hypertension. Hypertension 2003;42:1-7.
57. Vlachakis ND, Aledort L. Platelet aggregation in relationship to plasma catecholamines in patients with hypertension. Atherosclerosis 1979;32:451-60.
58. Varani K, Gessi S, Caiazza A, Rastelli G, Portaluppi F, Borea PA. Platelet alpha2-adrenoceptor alterations in patients with essential hypertension. Br J Clin Pharmacol 1999;47:167-72.
59. Reinders JH, de Groot PG, Sixma JJ, Van Mourik JA. Storage and secretion of von Willebrand factor by endothelial cells. Haemostasis 1988;18:246-61.
60. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995;90:244-8.
61. Morange PE, Simon C, Alessi MC, the PRIME study group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004;109:1343-8.
62. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GYH. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with atrial fibrillation. Circulation 2003;107:3141-5.
63. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van De Loo JCW. Haemodynamic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
64. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Cataprano G et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994;344:14-8.
65. Wagner DD, Bonfanti R. von Willebrand factor and the endothelium. Mayo Clin Proc 1991;66:621-7.
66. Moroi M, Jung SM. Integrin mediated platelet adhesion. Front Biosci 1998;3:719-28.
67. Nomura S, Imamura A, Okuno M, Kamiyama Y, Fujimura Y, Ikeda Y et al. Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines. Thromb Res 2000;98:257-68.
68. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986;78:340-8.
69. Gawaz M, Ott I, Reininger AJ, Heinzmann U, Neumann FJ. Agglutination of isolated platelet membranes. Arterioscler Thromb Vasc Biol 1996;16:621-7.
70. Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A et al. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 1997;96:1809-18.
71. McEver RP. The clinical significance of platelet membrane glycoproteins. Hematol Oncol Clin North Am 1990;4:87-105.
72. Okumura T, Jamieson GA. Platelet glycoprotein. I. Orientation of glycoproteins of the human platelet surface. J Biol Chem 1976;251:5944-9.
73. Krejsek J, Loudova M, Kopecky O. Blood platelet adhesion molecules. Cas Lek Cesk 1997;136:624-6.
74. Packham MA. Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol 1994;72:278-84.
75. Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstmann LL, Valle M et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003;41:211-7.
76. McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells 1990;16:73-80.
77. Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989;59:305-12.
78. Merten M, Pakala R, Thiagarajan P, Benedict CR. Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation 1999;99:2577-82.
79. Kamath S, Blann AD, Lip GY. Platelets and atrial fibrillation. Eur Heart J 2001;22:2233-42.
80. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabet Care 2001;24:1476-85.
81. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment. Circulation 2002;105:1503-8.
82. Diez J, Querejeta R Lopez B, Gonzalez A, Larman M, Ubango JLM. Losartan dependent regression of myocardial fibrosis is associated with reduction of left ventricle chamber stiffness in hypertensive patients. Circulation 2002;105:2512-7.
83. Lopez B, Gonzalez A, Varo N, La viades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38:1222-6.
84. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-40.
85. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-96.
86. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003;17:119-24.
87. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000;75:43-7.
88. Tayebjee M, Nadar S, Blann AD, Beevers DG, Macfadyen R, Lip G. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004;17:764-9.
89. Tayebjee M, Nadar S, Macfadyen RJ, Lip G. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004;17:770-4.
90. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40:136-41.
91. Kaizuka M, Yamabe H, Osawa H, Okumura K, Fujimoto N. Thrombin stimulates synthesis of type IV collagen and tissue inhibitor of metalloproteinases-1 by cultured human mesangial cells. J Am Soc Nephrol 1999;10:1516-23.
92. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
93. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z. Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 2003;10:136-41.
94. Jackson C. Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens 2002;11:295-9.
95. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906-11.
96. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep JG. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J 2001;15:2230-40.
97. Rossi GP, Andreis PG, Colonna S, Albertin G, Aragona F, Belloni AS et al. Endothelin-1[1-31]: a novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. J Clin Endocrinol Metab 2002;87:322-8.
98. Rothermund L, Vetter R, Dieterich M, Kossmehl P, Gogebakan O, Yagil C et al. Endothelin-A receptor blockade prevents left ventricular hypertrophy and dysfunction in salt-sensitive experimental hypertension. Circulation 2002;106:2305-8.
99. Porreca E, Di Febbo C, Mincione G, Reale M, Baccante G, Guglielmi MD et al. Increased transforming growth factor-b production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997;30(Pt 1):134-9.
100. Edwards DR, Murphy G, Reynolds JJ, Whithman SE, Docherty AJ, Angel P et al. TGF-b modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899-904.
101. Thuillez C, Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens 2005;19:S21-S25.
102. Boos CJ, Lip GYH. Is hypertension an inflammatory process? Curr Pharm Des 2006;12:1623-35.
103. Sanz-Rosa D, Oubina MP, Cediel E, de Las Heras N, Vegazo O, Jimenez J et al. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol 2005;288:H111-5.
104. Dernellis J, Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. Hypertension 2005;45:426-31.
105. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005;46:1118-22.
106. Nagano M, Nakamura M, Sato K, Tanaka F, Segawa T, Hiramori K. Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. Atherosclerosis 2005;180:189-95.
107. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004;24:969-74.
108. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004;17:568-73.
109. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-51.
110. Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen VP, Fuentes R et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004;44:859-65.
111. Grundy SM. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003;290:3000-2.
112. Duprez DA. Relationship between C reactive protein and arterial stiffness in asymptomatic population. J Hum Hypertens 2005;19:515-9.
113. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11.
114. Batistuta LE. Inflammation, endothelial dysfunction and the risk of high blood pressure: epidemiological and biological evidence. J Hum Hypertens 2005;17:223-30.
115. Nilsson J. CRP-marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005;25:1527-8.
116. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8.
117. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
118. Erratum in: JAMA 2003;289:178.
119. JAMA 2004;291:2196.
120. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;36:895-906.
121. Taddei S. Lacidipine restores endothelium dependent vasodilation in essential hypertensive patients. Hypertension 1997;30:1606-12.
122. Taddei S. Effect of calcium antagonist or beta blockade treatment on nitric oxide dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001;19:1379-86.
123. Cockcroft JR. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO dependent mechanism. J Pharmacol Exp Ther 1995;374:1067-71.
124. Kubli S, Feihl F, Waeber B. Beta blockade with nebivolol enhances the acetyl choline induced cutaneous vasodilation. Clin Pharmacol Ther 2001;69:238-44.
125. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40.
126. Erratum in: BMJ 2004;328:926.
127. Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yosefy C. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens 2005;19:667-73.
128. Felemden DC, Lip GYH. Antithrombotic therapy in hypertension: a Cochrane systematic rewiew. J Hum Hypertens 2005;19:185-96.